Drugs / JNJ-75220795
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05039710 | Nov 2021 → Feb 2023 | fatty liver disease | Janssen Pharmaceutical K.K. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04844450 | Apr 2021 → Mar 2023 | fatty liver disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-17 | Arrowhead Pharmaceuticals | Arrowhead Announces JNJ-75220795 in Development for NASH arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-75220795 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04844450 ↗ |
| Route | Subcutaneous | “JNJ-75220795 will be administered subcutaneously.” NCT04844450 ↗ |